Taft Pharmaceutical & Life Sciences attorneys Richard Ruzich and Roshan Shrestha will present on 12(b)(6) and 12(c) motions at the 9th Annual Pharma IPR Conference in Mumbai, India on March 4-6, 2020. The conference brings together key stakeholders, IP Attorneys and Counsels from across the globe to discuss, deliberate and share their thoughts on achieving the next phase of growth, recent trends and best practices in the Pharma IPR space. More information is here.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilars sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.
Shrestha focuses his practice on all aspects of intellectual property law, including patent litigation, prosecution and opinion work in the chemical, pharmaceutical and electronic material arts. He has a broad scope of pharmaceutical and life sciences capabilities, including Hatch-Waxman litigation and inter partes review proceedings at the USPTO. Shrestha has been recognized by Super Lawyers as a Rising Star since 2014. In 2016, he was named to Law Bulletin’s “40 Illinois Attorneys Under 40 to Watch.” Before practicing law, Shrestha was a research scientist at Los Alamos National Laboratory in New Mexico, where his investigation on materials for hydrogen storage technology received several patents.